Topics

Pfizer and Merck KGaA's Bavencio falls short of primary endpoint in Phase 3 gastric cancer trial

10:30 EST 8 Nov 2019 | Pharmafile

Pfizer and Merck KGaA’s EMD Serono have lifted the lid on new Phase 3 data for Bavencio (avelumab) in the treatment of gastric cancer, and they were not the promising kind.

In evaluating the therapy for maintenance treatment following induction chemotherapy in unresectable, locally advanced or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) cancer, the companies found that while it showed clinical activity, it failed to outclass chemotherapy or best supportive care with regards to extend overall survival.

read more

Original Article: Pfizer and Merck KGaA's Bavencio falls short of primary endpoint in Phase 3 gastric cancer trial

NEXT ARTICLE

More From BioPortfolio on "Pfizer and Merck KGaA's Bavencio falls short of primary endpoint in Phase 3 gastric cancer trial"

Quick Search

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...